FDA grants fast track designation to Arrowhead Pharmaceuticals’ ARO-APOC3 to reduce triglycerides

Image: Arrowhead Pharmaceuticals develops medicines to treat intractable diseases by gene silencing approach. Credit: Gerd Altmann from Pixabay.